NCT06086704View on ClinicalTrials.gov

Study of 18F-FFNP Breast PET/MRI

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 25, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2030

Conditions
Breast Cancer
Interventions
DRUG

18F-fluorofuranylnorprogesterone

18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.

DEVICE

Positron Emissions Tomography / Magnetic Resonance Imaging

Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)

DRUG

Anastrozole

hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days

OTHER

Blood Sampling

Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions

DRUG

FDA-approved gadolinium-based intravenous contrast agent

FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study

Trial Locations (1)

53792

RECRUITING

UW Carbone Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER